GILD

Merger Mania: 4 Major Deals to Watch

By Louis Navellier, Editor, Growth Investor
It’s an exciting time for mergers and acquisitions in some of the hottest sectors -- including software, cloud services, artificial intelligence and health care. Here are four major mergers to watch.

Immunomedics News: IMMU Stock Skyrockets 99% on Gilead Deal

By William White, InvestorPlace Writer
Immunomedics (IMMU) is seeing IMMU stock soar higher Monday following news that it will be acquired by Gilead (GILD) for $21 billion.

5 of the Best Pharmaceutical Stocks to Buy Right Now

By David Moadel, InvestorPlace Contributor
A handful of pharmaceutical stocks have been on fire lately, but I'm writing for a "buy" prescription for five of the best names now.

4 Pharmaceutical Stocks With Deep Pipelines

By Larry Ramer, InvestorPlace Contributor
Coronavirus vaccines get all the attention, but these four pharmaceutical stocks benefit from equipment, drug and test kit developments.

What Happened to Gilead Sciences and Is the Stock Still a Buy?

By InvestorPlace Research Staff
Gilead stock has been under pressure for a few months, giving investors a great risk/reward setup, especially with its coronavirus treatment.

Remdesivir Data Leaves Gilead Stock Well-Positioned to Rally

By Larry Ramer, InvestorPlace Contributor
Strong sales of Gilead's successful novel coronavirus drug, remdesivir, will ultimately lift GILD stock and reward shareholders.

30 Dividend Stocks to Buy Now for 20 Years of Income Growth

By Josh Enomoto, InvestorPlace Contributor
With a 20-year timeline, you have multiple choices for dividend stocks to buy. Here are 30 names that should do very well.

4 Coronavirus Stocks to Buy as the Pandemic Rages On

By Faisal Humayun, InvestorPlace Contributor
As the pandemic continues to grow, these four coronavirus stocks are great ways to protect your portfolio for the foreseeable future.

Quick Income from a Put Write on Johnson & Johnson

By Ken Trester
Earnings season is upon us, and Johnson & Johnson (NYSE:JNJ) will kick off second-quarter reporting for the big pharmaceutical stocks on July 16.

4 Pharmaceutical Stocks to Watch for the Rest of 2020

By Faisal Humayun, InvestorPlace Contributor
As pharmaceutical companies rush to manufacture coronavirus vaccine and drugs, it makes sense to hold some potential winners.

10 Stocks Riding on the Covid-19 Recovery

By Josh Enomoto, InvestorPlace Contributor
With pandemic fears shuttering many economies, most investments have cratered. However, a small group of coronavirus stocks may offer significant upside potential.

7 Cash Stocks to Invest in As Markets Turn Negative

By Thomas Niel, InvestorPlace Contributor
Consider these seven cash stocks (both defensive and cyclical) as strong buys with upside relative to risk, as markets continue to yo-yo.

Gilead Gets a Boost From Positive Coronavirus Research

By Larry Ramer, InvestorPlace Contributor
Signs continue to mount that remdesivir is a highly effective treatment for the coronavirus. The drug will move the needle for GILD stock.

Remdesivir Can’t Cure Covid, But Good Luck Telling Gilead Stock

By Dana Blankenhorn, InvestorPlace Contributor
Gilead is moving into commercial production of Remdesivir, a COVID-19 treatment with an aggressive pricing model, but other biotech solutions could come out ahead; it's early days still.

Gilead Stock Is Worth Owning With or Without a Coronavirus Cure

By InvestorPlace Research Staff
GILD stock has been rallying, but it has been running out of momentum lately. Just don't lose focus on the positives for Gilead.

Stock Market Today: Coronavirus Treatments Make Progress; Nvidia to $425?

By Bret Kenwell, InvestorPlace Contributor
Nvidia caught a huge price target increase, while Apple looks to reopen its stores. Here's what happened in the stock market today.

Buy Good News Gilead Stock Before Other Investors Catch On

By Larry Ramer, InvestorPlace Contributor
Positive signs continue to mount for remdesivir, yet the market continues to have mixed feelings about GILD stock.

Gilead Stock Still Looks Poised to Prove the Bears Wrong

By Larry Ramer, InvestorPlace Contributor
With remdesivir poised to become a blockbuster drug for Gilead, GILD stock still looks poised to prove the bears wrong

9 Enduring Stocks That You Shouldn’t Sell in May

By Josh Enomoto, InvestorPlace Contributor
Under any other circumstance, sell in May and go away may be considered a sound strategy. In this crisis, though, you may want to keep these stocks to buy for the long haul.
Load More